Bridging animal health and diagnosis
Through unrivaled technology
  • 1
  • 3
Core technology
Ceaseless challenges and changes
Innovative bio-technology
  • 2
  • 3
Bio-contents
Solution Partner for Healthy
Coexistence of Humans and Animals
  • 3
  • 3
Global leader
    PRODUCT Introducing BIONOTE’s Products.
    • Rapid Immunoassay
      Rapid
    • Fluorescence Immunoassay
      Vcheck F
    • Enzyme Immunoassay
      ELISA
    • Molecular Diagnostics
      Vcheck M
    • Biochemistry
      Vcheck C
    NEWS Stay in the know of the latest Bionote updates. More
    Bionote Participates in the Largest Veterinary Conference in the Yeongnam Region

      Bionote participated in the 12th Yeongnam Veterinary Conference held at Changwon Convention Center from July 23rd to 24th. As the largest veterinary conference in the Yeongnam region, it is also considered one of the top three veterinary conferences held in Korea.  Due to COVID-19, the Yeongnam Veterinary Conference has been held online for the year 2020 and 2021. This is the first time in three years that it has finally been held as an in-person event. The theme for the 12th conference was ‘Back to Basic’, with 31 lecturers on various topics such as internal medicine, dentistry, skin, and cardiac.  Despite the spread of COVID-19, more than 1,000 veterinarians and veterinary school students visited the conference. Bionote also participated in the conference through booth operation, focusing on promoting the Feline TnI, which will soon be launched in the following August. There was also a free sample giveaway which was met with high consumer demand. Feline TnI is a test marker for a quantitative measurement of Troponin I in feline serum and can be used on Bionote’s immunofluorescence analyzer Vcheck F series. This marker is especially useful for screening hypertrophic cardiomyopathy (HCM), which is a common cardiac disease in cats. As with its largest installation share in the Korean veterinary market, many of the Vcheck F users have visited the Bionote booth and showed great interest in the soon-to-be-launched product.  Bionote plans to participate in additional conferences in Busan and Seoul and will continue to communicate with its customers throughout.

    2022.08.02
    BIONOTE Webinar on Vcheck Feline SAA successfully held on June 2nd

    BIONOTE Webinar on "Cat Inflammation Diagnosis and Biomarker" was successfully held on June 2nd with nearly 600 veterinarians present. Dr. Yoo, director of Dr. Cat animal hospital, appeared as a speaker.                                     Dr. Yoo emphasized the need for SAA tests for inflammatory screening purposes in cats visiting the hospital with non-specific clinical symptoms such as loss of appetite, weight loss, and depression. SAA (Serum amyloid A) is one of the acute phase proteins (APPs) secreted by the liver by inflammatory stimulation and is a useful inflammatory indicator in cats. When there are inflammatory stimuli such as tissue injury, infection, and muscle breakdown, monocytes and macrophages are activated, causing the secretion of cytokines such as IL-6. This stimulates the liver to release several APPs such as CRP, SAA, and Haptoglobin, causing systemic inflammatory reactions, including leukocytosis. Since the secretion of APPs precedes the increase in white blood cells, an increase in SAA levels can be observed earlier than the WBC levels in inflammatory situations. SAA begins to increase within 3 hours of inflammatory stimulation, reaching its peak after 48-72 hours. This biomarker increases in situations such as acute and chronic inflammation, infection, necrosis, injury, and malignant tumors. Therefore, SAA is widely understood as a marker capable of initial diagnosis of inflammation or infection, and is considered a basic test item in cats with clinical symptoms. It can also be used for monitoring purposes in cats before and after surgery. A good prognosis can be expected if SAA levels reach their peak 2-3 days after surgery and return to normal within 7 days, but if high SAA levels continue to be maintained, it suggests that there is postoperative infection. However, in the case of liver disease, careful interpretation is required with other diagnostic tools, because SAA levels may be low even in inflammatory situations because APPs are not sufficiently produced. Finally, Dr. Yoo provided easy guidance to the clinical usability through several real-case introductions using SAA in various diseases such as chronic rhinosinusitis, viral infection (herpesvirus, calicivirus), and feline infectious peritonitis (FIP). BIONOTE released the Vcheck Feline SAA 3.0 kit last year. Vcheck Feline SAA is a biomarker for inflammation diagnosis and monitoring in cats (Learn more). This kit can be quantitatively measured using a fluorescent immunoassay analyzer (Vcheck) in a short time (5 minutes) and can be tested using a small amount of sample (serum, plasma 5 µl). If you are interested in Vcheck Feline SAA 3.0, please contact your local distributor or send your request to [bionote@bionote.co.kr].  

    2022.06.08
    SDB Investment Chairman Young-Sik Cho donated KRW 25 billion for the development of the bio-industry

    SDB Investment is donating KRW 25 billion(₩) to Seoul National University.   Seoul National University held a signing ceremony for Bionote, Inc., in the presence of key figures from the school including President Se-Jeong Oh, Vice President of Planning Won-Woo Lee, Dean of Veterinary Medicine Ho-Jae Han, and many others. A plaque of appreciation has also been delivered to SD Biosensor/Bionote Chairman Cho Young-Sik. After graduating from Seoul National University's College of Veterinary Medicine in 1984, Cho joined Green Cross, a pharmaceutical company. There, he was in charge of developing diagnostic reagent and product production for 13 years, and also served as a manager for domestic and overseas marketing division. During his career, he graduated from Seoul National University College of Veterinary Medicine with Master's and Doctorate degrees in veterinary biochemistry to further improve his professional capabilities. As the current chairman of SD Biosensor, Inc., and the CEO of SDB Investment, Cho has successfully founded SD Biosensor and Bionote to be a global diagnostic company for the human and veterinary field each.   "For the past 2 years, humanity has suffered the unforeseen pandemic. Such illness can easily be eradicated with the cutting-edge technology utilizing A.I. (Artificial Intelligence)," said Cho. "Korea needs to actively support on the A.I. program to help flourish the bio industry." "I hope the contribution made today can be the stepping stone for the Korea's biotechnology industry." said Cho.  Among the ₩25 billion donation, ₩20 billion will be dedicated to ‘Data Center Research Fund’ to build a GPU-based data center and support convergence research. Remaining ₩5 billion will be dedicated to the ‘Education and Research Environment Improvement Project Fund of the College of Veterinary Medicine’.  Seoul National University has claimed that the donation will be cherished to support excellent researchers to induce innovation and growth.

    2022.04.29
    2nd National Veterinary Advisory Council (NVAC) held at Bionote

    The Korean Veterinary Association held 2nd National Veterinary Advisory Council (NVAC) at Bionote, Inc., on April 26th, 2022. The NVAC is an official advisory body within the Veterinary Society, providing advice to the government on the prevention of malignant livestock diseases such as FMD, ASF and major zoonotic diseases, while also serving to establish an official veterinary medical system.    Key figures at NVAC 2022 includes: Chairman Yong-Ho Park (Seoul National University Veterinary College), ▲ Jong-Gu Kang (Biotoxtech), ▲ Jong-Kil Kang (Chunghyeon General Veterinary Hospital), ▲ Gon-Seop Kim (Gyeongsang National University Veterinary College), ▲ Woo-Joo Kim (Korea University Guro Hospital), ▲ Young-Soo Ryu (Konkuk University Veterinary College) , ▲Seungwon Seo (Boehringer Ingelheim Veterinary Medicine), ▲Sangcheol Shin (Solgent), ▲Chunggeun Yoon (Asia Veterinary Hospital), ▲Soodu Lee (Ministry of Food and Drug Safety), ▲Poongkyu Lee (Knowhere bio), ▲Youngsik Cho (Bionote). For this year's council meeting, Professor Kim Woo-Joo, Department of Infectious Diseases at the Korea University Guro Hospital, discussed the current status of the COVID-19 pandemic, development of vaccines, changes due to the emergence of mutants, and future prospects and countermeasures, under the theme of 'COVID-19 Pandemic: Current Status and Prospects'. Bionote is the No. 1 manufacturer for veterinary diagnostic reagents in Korea. For its post pandemic growth engine,  Bionote will be focusing on expanding its business sector via molecular diagnostic analyzer Vcheck M, biochemistry analyzer Vcheck C, and bio-contents business.

    2022.04.26
    Excellent performance verification of Vcheck Canine NT-proBNP (SCI journal)

    A paper on the analytical validation of Vcheck Canine NT-proBNP (BIONOTE) has been published in the international journal, Veterinary Clinical Pathology (Science Citation Index, Impact factor 1.18).Paper: Analytical validation of a novel point-of-care immunoassay for canine N-terminal pro-brain natriuretic peptide analysis (Vet Clin Pathol. 2022;00:1–10.) See the attached document for the summary and click here for the full paper (open access).   This study aimed to analytically validate a Vcheck NT-proBNP assay according to American Society of Veterinary Clinical Pathology (ASVCP) and Clinical Laboratory Improvement Amendments (CLIA) specifications.   Precision Imprecision was considered acceptable with a coefficient of variation ranging from 9% at 4000 pmol/L to 20% at 600 pmol/L.   Accuracy Comparison of the Vcheck assay with the Cardiopet NT-proBNP assay revealed an excellent correlation with minimal bias (y=0.9x+37, R2=0.9) when preanalytical factors were controlled.   Preanalytical error Significant degradation of NT-proBNP occurred when current methods were used at refrigerated (average loss of 20%) and room temperatures (loss of at least 50%), which could change diagnostic and prognostic decision-making.   Interferents (analytical specificity) Spiking samples across the linear range of the assay with 35 mg/dL hemoglobin and 1000 mg/dL Intralipid did not reveal a statistically significant difference.   Reference intervals Age-partitioned reference intervals (95%) have upper reference limits of 750 pmol/L and 1280 pmol/L for 36 juvenile and 125 adult dogs, respectively.     According to this study, the Vcheck assay provides analytically acceptable results. Onsite testing can minimize variability related to preanalytical error and provide clinically useful contemporaneous results.   Also, the author emphasized that samples should be centrifuged immediately and analyzed within 2 hours of collection, due to significant degradation of NT-proBNP.   Results of this study demonstrate that the Vcheck NT-proBNP assay is a valid point-of-care cardiac biomarker using the canine serum.   Vcheck Canine NT-proBNP can be quantitatively measured using a fluorescent immunoassay analyzer (Vcheck) in a short time (15 minutes) and can be tested using a small amount of sample (serum 100 µl). Learn more

    2022.04.07
    BioNote USA, attending the Western Veterinary Conference which is the largest Veterinary Science Society in the United States

    Bionote USA attended the Western Veterinary Conference to be held March 6th to March 9th, 2022 at the Mandalay Bay Convention Center in Las Vegas, Nevada.WVC’s Annual Conference is one of the largest, most influential gatherings of veterinary professionals in the world. Bionote USA communicated with veterinary workers and vets who attended the conference through participation in the booth about how Vcheck could develop and help veterinary medicine.   On this day, renowned Dr. Rozanski sponsored by Bionote, spoke about the role of NT-proBNP in clinical decision making and the benefits of point-of-care testing. NT-proBNP is correlated with heart size and systolic function, suggesting that the concentrations can be used to detect dogs with early disease. In addition, Vcheck Canine NT-proBNP is an in vitro diagnostic test kit for the quantitative measurement of NT-proBNP concentration in canine serum. This test kit precisely quantifies the degree of elevation in NT-proBNP levels in dogs. The ability to distinguish cardiac from non-cardiac causes of respiratory signs is important for further decisions on diagnostics and therapy. NT-proBNP allows distinguishing cardiac from respiratory disease in dogs with dyspnea. Also, this marker helps to detect dogs with Myxomatous Mitral Valve Degeneration (MMVD), which is the most common heart disease in dogs. In dogs with stable Congestive Heart Failure (CHF) due to MMVD, NT-proBNP is of value in monitoring the effectiveness of medical treatment for CHF. In large breeds, Dilated Cardiomyopathy (DCM) is the most common cause of heart disease. Annual screening tests are recommended to determine if DCM is present even if dogs at elevated risk are healthy. The measurement of NT-proBNP increases the diagnostic accuracy with Holter monitoring (91% accuracy). Vcheck Canine NT-proBNP: The one-step test procedure is easy to follow and provides fast results within 15 minutes using serum samples from dogs. Bionote USA completed the 2022 Western Veterinary Conference, and in addition, Bionote KOREA and Bionote CHINA also plan to hold various external activities and conferences. 

    2022.03.14
    NowCheck COVID-19 Spike IgG Test Obtains CE Mark … Awaiting for the U.S. FDA EUA

       | The SARS-CoV-2 Antibody for Spike IgG can be detected within 15 minutes | Completed CE mark certification and is awaiting FDA Emergency Use Authorization.   Bionote has announced the acquisition of CE marking for its NowCheck™ COVID-19 Spike IgG Test to detect specific antibodies to SARS-CoV-2. This is the company’s third addition to the existing COVID-19 product portfolio, following the NowCheck™ COVID-19 Ag Test and COVID-19 IgM/IgG Test.  Antibody rapid diagnostic test is a widely used screening method for determining antibodies in the blood of people who have been previously infected with or vaccinated against a virus that causes a disease. The test procedure for a rapid test is simple, fast, and efficient, requiring only 15 to 30 minutes without the need for any additional equipment.  COVID-19 vaccines are becoming mandatory in many countries around the globe, and among the vaccines, the major type is the mRNA vaccine which uses the spike protein. As the number of people receiving the COVID-19 mRNA vaccine increases, the demand for COVID-19 antibody testing is also growing.  Currently, the plaque reduction neutralization test (PRNT) is considered the gold standard for measuring levels of the antibodies for many viral diseases, but as the PRNT requires biological safety level 3 laboratory (BSL3), this testing method has limitations with wide implementation. Compared to the PRNT test, antibody rapid diagnostic test can quickly be performed without any need for a standardized environment.  Bionote’s NowCheck COVID-19 Spike IgG Test can detect specific antibodies against SARS-CoV-2 within 15 minutes. This test also demonstrated high accuracy in the clinical evaluation using a total of 102 serum specimens, with percent positive agreement of 82% (41/50) and percent negative agreement of 100% (52/52).  Bionote is expecting the demand for COVID-19 antibody testing to continue to increase as more people receive vaccination and begin to realize the importance of immunity. The company is planning to launch its NowCheck COVID-19 Spike IgG Test in the U.S. market soon after its completion of the U.S FDA EUA.  For those who are interested in NowCheck COVID-19 Tests, please contact your local distributor or mail to [bionote@bionote.co.kr]. 

    2022.01.11